PATENT CLAIM ANALYSIS

Application Number: 15974647
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2018-11
Patent Classification: ["424", "186100"]

Abstract:
The present invention relates to an EBV antigen specific T-cell receptor and the use thereof. Specifically, the present invention provides T cells specific for LMP1 of EBV using a T-cell receptor which is highly specific for specific epitopes derived from an EBV antigen, LMP1. In addition, the EBV antigen specific T-cell can be used in the prevention or treatment of EBV-associated diseases.

Claim (Index 5):
The method of  claim 1 , wherein the EBV-associated disease is EBV-positive Hodgkin lymphoma, EBV-positive nasopharyngeal carcinoma, or EBV-positive post-transplant lymphoproliferative disease (PTLD).

Metadata:
- Claim Count in Document: 9.0
- Percentile: 93.0
- Lexical Diversity: 1.5814
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['14928762', '12091705', '10496861', '15735133', '11359868']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7204260044846953
- 35 USC 102 Novelty (BERT): 0.5920142465116313
- Combined Prediction Score: 0.7075848286873889
- Mean Citation Score: 346.9232100000001
- Max Citation Score: 570.47107
- Similarity Product: 385.6407889640147

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test